Meeting
2012 ASCO Annual Meeting
Phase II study of preoperative radiation with concurrent capecitabine, oxaliplatin, and bevacizumab followed by surgery and postoperative 5-FU, leucovorin, oxaliplatin (FOLFOX), and bevacizumab in patients with locally advanced rectal cancer: A trial of the Eastern Cooperative Oncology Group (E3204).
Authors
Steven J. Cohen
Fox Chase Cancer Center, Philadelphia, PA
Steven J. Cohen , Yang Feng , Jerome Carl Landry , Charles A. Staley , Richard Whittington , Elin R. Sigurdson , Halla Sayed Nimeiri , Udit N. Verma , Al Bowen Benson
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer
Clinical Trial Registration Number
NCT00321685
Citation
J Clin Oncol 30, 2012 (suppl; abstr 3605)
DOI
10.1200/jco.2012.30.15_suppl.3605
Abstract #
3605
Poster Bd #
35B
Abstract Disclosures
Similar Posters
Poster
2013 Gastrointestinal Cancers Symposium
A novel preoperative protocol for locally advanced rectal cancer: Hyperfractionated short-course radiotherapy combined with chemotherapy.
First Author: Hiroshi Doi
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Total neoadjuvant therapy (TNT) for locally advanced rectal cancer (LARC): Real-world experience from a tertiary Asian cancer center.
First Author: Meng Wang
Poster
2021 Gastrointestinal Cancers Symposium
Short-course radiotherapy and subsequent CAPOX plus camrelizumab followed by delayed surgery for locally advanced rectal cancer: Short-term results of a phase II trial.
First Author: Zhenyu Lin
Poster
2021 Gastrointestinal Cancers Symposium
Neoadjuvant chemotherapy with modified FOLFOXIRI for locally advanced rectal cancer: A single center phase II trial.
First Author: Wen Zhang